Merck KGaA

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:03 13/09/2024 BST			5-day change	1st Jan Change
168.20 ^EUR	-0.21%		-0.36%	+16.72%

09-13	MERCK KGAA : UBS keeps its Buy rating	ZD
09-09	German Shares Cheer Likelihood of September ECB Rate Cut	MT

JPMorgan rates Merck KGaA at 'Overweight' - Target 190 euros

August 09, 2024 at 10:00 am

NEW YORK (dpa-AFX Broker) - The US bank JPMorgan has left its rating for Merck KGaA at "Overweight" with a target price of 190 euros after the figures for the second quarter. The recovering electrical and life science businesses of the pharmaceutical and specialty chemicals company are still not valued highly enough by investors, analyst Richard Vosser wrote in a study published on Friday./mis/ajx

Publication of the original study: 08.08.2024 / 22:56 / BST

First distribution of the original study: 09.08.2024 / 00:15 / BST

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------

Go to the original article.
Legal disclaimer

Latest news about Merck KGaA

MERCK KGAA : UBS keeps its Buy rating	09-13	ZD
German Shares Cheer Likelihood of September ECB Rate Cut	09-09	MT
Merck Gets EU Approval for Keytruda Cancer Therapy	09-03	DJ
Merck KGaA Doses First Patient in Late-stage Myasthenia Gravis Study	08-29	MT
Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis	08-29	CI
Chemical and pharmaceutical industry: research spending to remain virtually stable	08-29	DP
Merck KGaA Plans EUR800 Million Issuance of Subordinated Hybrid Instruments	08-20	MT
JPMorgan rates Merck KGaA at 'Overweight' - Target 190 euros	08-09	DP
MERCK KGAA : JP Morgan maintains a Buy rating	08-09	ZD
Bernstein: Sanofi Set to Record Growth on Expected Multiple Sclerosis Boost	08-08	MT
Biotech firm Recursion to buy smaller peer Exscientia for $688 million	08-08	RE
MERCK KGAA : UBS raises price target	08-07	CF
MERCK KGAA : Receives a Buy rating from UBS	08-06	ZD
MERCK KGAA : Gets a Buy rating from Deutsche Bank	08-06	ZD
MERCK KGAA : DZ Bank reaffirms its Buy rating	08-05	ZD
MERCK : All lights are green for a robust H2	08-02
Global markets live: Shell, Chevron, Boeing, Walt Disney, Qualcomm...	08-01
Germany's Merck KGaA Wraps Up Acquisition of US-based Mirus Bio	08-01	MT
Merck KGaA increases sales - Semiconductors and Pharmaceuticals provide support	08-01	DP
Transcript : Merck KGaA, Q2 2024 Earnings Call, Aug 01, 2024	08-01
MERCK KGAA : Jefferies gives a Buy rating	08-01	ZD
MERCK KGAA : UBS reiterates its Buy rating	08-01	ZD
MERCK KGAA : Gets a Buy rating from Barclays	08-01	ZD
MERCK KGAA : Deutsche Bank remains its Buy rating	08-01	ZD
MERCK KGAA : JP Morgan reiterates its Buy rating	08-01	ZD

Chart Merck KGaA

Duration

Period

More charts

Company Profile

Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (44.2%); - pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.; - performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc. Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).

Employees

62,176

Sector

Pharmaceuticals

Calendar

16/10/2024 - Capital Markets Day

More about the company